Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval

The European Commission (EC) has approved BioMarin Pharmaceutical Inc's BMRN Voxzogo (vosoritide) once-daily injection to treat achondroplasia.
The approval covers children from 2 years until growth plates are closed, which occurs after puberty when children reach final adult height.
Voxzogo is a modified C-type natriuretic peptide (CNP) that directly downregulates fibroblast growth factor receptor 3 (FGFR3) signaling and promoting endochondral bone formation.
The FDA's US application for Voxzogo is under review with a target action date of November 20.
Related content: Benzinga's Full FDA Calendar
Price Action: BMRN stock is up 6.48% at $83.98 on the last check Friday.

Momentum17.60

GrowthNot Available

Quality29.29

Value66.43

Short

Medium

Long